CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone

First Posted Date: 2013-11-28

Last Posted Date: 2025-03-04

Lead Sponsor: Celgene

Target Recruit Count: 103

Registration Number: NCT01997840

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Local Institution - 201, Boston, Massachusetts, United States

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Phase 3

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2013-11-27

Last Posted Date: 2024-10-01

Lead Sponsor: Celgene

Target Recruit Count: 503

Registration Number: NCT01996865

Locations: 🇺🇸
Local Institution - 011, Marietta, Georgia, United States
🇺🇸
Local Institution - 056, Niles, Illinois, United States
🇺🇸
Local Institution - 028, Park Ridge, Illinois, United States

and more 123 locations

A Phase 1 QT Study in Healthy Male Subjects

Phase 1

Completed

Conditions: Clinical Pharmacology, Healthy Volunteer Study

Interventions: Drug: Placebo
Drug: Pomalidomide
Drug: Moxifloxacin

First Posted Date: 2013-11-19

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 72

Registration Number: NCT01986894

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CC-292
Drug: Placebo

First Posted Date: 2013-11-03

Last Posted Date: 2017-07-31

Lead Sponsor: Celgene

Target Recruit Count: 47

Registration Number: NCT01975610

Locations: 🇺🇸
NYU Langone Medical Center, New York, New York, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Family Arthritis Center, Jupiter, Florida, United States

and more 24 locations

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

Phase 3

Completed

Conditions: Pancreatic Neoplasms
Neoplasms
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Endocrine System Diseases
Gemcitabine
Antimetabolites, Antineoplastic

Interventions: Drug: nab-Paclitaxel
Drug: Gemcitabine

First Posted Date: 2013-10-17

Last Posted Date: 2023-06-28

Lead Sponsor: Celgene

Target Recruit Count: 866

Registration Number: NCT01964430

Locations: 🇺🇸
Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸
Local Institution - 023, Chattanooga, Tennessee, United States
🇺🇸
Local Institution - 010, Dallas, Texas, United States

and more 338 locations

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Rhabdomyosarcoma
Ewing's Tumor
Sarcoma, Spindle Cell
Pediatrics, Osteosarcoma
Osteosarcoma Tumor
Sarcoma, Osteogenic
Sarcomas, Epitheliod
Malignant Melanoma
Tumors

Interventions: Drug: nab-paclitaxel

First Posted Date: 2013-10-14

Last Posted Date: 2019-12-27

Lead Sponsor: Celgene

Target Recruit Count: 107

Registration Number: NCT01962103

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇮🇹
l'Azienda Ospedaliera Regina Margherita - Sant Anna, Torino, Italy
🇨🇭
Universitäts-Kinderklinik, Zurich, Switzerland

and more 17 locations

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid (lenalidomide)

First Posted Date: 2013-09-20

Last Posted Date: 2017-01-12

Lead Sponsor: Celgene

Target Recruit Count: 176

Registration Number: NCT01947309

Locations: 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳
Xiangya Hospital Central-South University, Changsha, China
🇨🇳
Shanghai Changzhen Hospital, Shanghai, China

and more 14 locations

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2013-09-19

Last Posted Date: 2025-06-06

Lead Sponsor: Celgene

Target Recruit Count: 186

Registration Number: NCT01946477

Locations: 🇺🇸
Local Institution - 128, Lubbock, Texas, United States
🇺🇸
Local Institution - 106, Spokane, Washington, United States
🇨🇦
Local Institution - 113, Calgary, Alberta, Canada

and more 46 locations

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Phase 3

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Rituximab
Drug: Placebo
Drug: Lenalidomide

First Posted Date: 2013-09-10

Last Posted Date: 2023-02-22

Lead Sponsor: Celgene

Target Recruit Count: 358

Registration Number: NCT01938001

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Arlington Cancer Center, Arlington, Texas, United States
🇨🇳
Beijing Cancer Hospital, Beijing, PR, China

and more 157 locations

Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide Celgene™

First Posted Date: 2013-09-09

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 7

Registration Number: NCT01937442

Locations: 🇫🇷
CHRU Hopital Brabois, Vandoeuvre Cedex, France
🇫🇷
CHRU-Hopital Claude Huriez, Lille, France
🇫🇷
Hopital Augustin Morvan, Brest Cedex, France

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy